Shenghui Integration's Indonesian subsidiary has secured a significant construction project valued at approximately 223 million RMB. This project involves the development of a shoe sole and footwear production facility. Separately, a subsidiary of Sunshine Nuohe has received approval for clinical trials for its STC009 injection, intended for treating secondary hyperparathyroidism. AI
IMPACT This cluster reports on a construction project win and a drug trial approval, with no direct impact on AI operators.
RANK_REASON The cluster contains news about subsidiaries winning contracts and receiving regulatory approval for drug trials, which are not frontier AI releases or significant industry-wide events.
- Chengdu Nuohe Shengtai Biotechnology Co., Ltd.
- National Medical Products Administration
- PT ACTER INTEGRATION TECHNOLOGY INDONESIA
- PT. Hardases Abadi Indonesia
- Shenghui Integration
- STC009 injection
- Sunshine Nuohe
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →